REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial

  • Company to host webcast on Tuesday, March 5, 2024 at 8:30 a.m. EST
  • Interim clinical data will be presented by Aravindhan Veerapandiyan, M.D., primary investigator of the AFFINITY DUCHENNE trial, at the MDA Clinical & Scientific Conference on Wednesday, March 6, 2024 at 12:00 p.m. EST

ROCKVILLE, Md., Feb. 29, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a live webcast to discuss new interim clinical data from the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for the treatment of Duchenne muscular dystrophy. Primary investigator Aravindhan Veerapandiyan, M.D. will join the webcast and be available for Q&A.

Webcast details
Title: Interim Clinical Data from Phase I/II AFFINITY DUCHENNE Trial of RGX-202 
Date/Time: Tuesday, March 5, 2024, at 8:30 a.m. EST
Access: The live webcast can be accessed in the Investors section of REGENXBIO's website at An archived replay of the webcast will be available for approximately 30 days following the presentation.

Muscular Dystrophy Association Clinical & Scientific Conference presentation details
Title: RGX-202, an investigational gene therapy for the treatment of Duchenne muscular dystrophy: Interim clinical data
Session: Clinical Trial Updates
Date/Time: Wednesday, March 6, 2024, 12:00 p.m. EST
Presenter: Aravindhan Veerapandiyan, M.D., Director of the Comprehensive Neuromuscular Program, PPMD Certified Duchenne Care Center, and Co-Director of the Muscular Dystrophy Association Care Center at Arkansas Children's Hospital

The presentation will be available in the Publications section of REGENXBIO's website.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit


Dana Cormack
Corporate Communications 

Chris Brinzey
ICR Westwicke

(PRNewsfoto/REGENXBIO Inc.)



Cision View original content to download multimedia:


Company Codes: NASDAQ-NMS:RGNX

Back to news